ROR1 Literature
ROR1 Biology and Targeting
Dec 2014 Seminars in Cancer Biology
The Receptor Tyrosine Kinase ROR1--an Oncofetal Antigen for Targeted Cancer Therapy
Jul 2015 Expert Opinion on Therapeutic Targets
Receptor Tyrosine Kinase-Like Orphan Receptor 1: A Novel Target for Cancer Immunotherapy
ROR1 Expression in Hematologic Malignancies and Solid Tumors
Sep 2008 International Journal of Cancer
Ror1, a Cell Surface Receptor Tyrosine Kinase Is Expressed in Chronic Lymphocytic Leukemia and May Serve as a Putative Target for Therapy
Dec 2012 American Journal of Pathology
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Apr 2013 Leukemia & Lymphoma
Orphan Receptor Tyrosine Kinases ROR1 and ROR2 in Hematological Malignancies
ROR1 Association with Tumor Aggressiveness and Adverse Outcomes
May 2012 PLoS One
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Nov 2016 Scientific Reports
ROR1 is a Novel Prognostic Biomarker in Patients with Lung Adenocarcinoma
Anti-ROR1 Monoclonal Antibody Development
Jun 2015 Clinical Lymphoma, Myeloma & Leukemia
Pre-clinical Specificity and Safety of UC-961, a First-in-class Monoclonal Antibody Targeting ROR1
Jun 2018 Cell Stem Cell
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
VLS-101 Nonclinical Activity
Nov 2019 American Society of Hematology Meeting
VLS-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)
Now Leaving The VelosBio Site.
VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)